Neurocognitive function in mild hyperphenylalaninemia

Developmental Medicine and Child Neurology

Volumn 53, Issue 5, 2011, Pages 405-408

  Campistol, Jaume ^a   Gassió, Rosa ^a   Artuch, Rafael ^a   Vilaseca, Ma Antonia ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PHENYLALANINE;

COGNITION; COGNITIVE DEFECT; DISEASE SEVERITY; HUMAN; HYPERPHENYLALANINEMIA; INTELLIGENCE QUOTIENT; PHENYLKETONURIA; PRIORITY JOURNAL; REVIEW;

COGNITION DISORDERS; HUMANS; NEUROPSYCHOLOGICAL TESTS; PHENYLKETONURIAS;

EID: 79954582736     PISSN: 00121622     EISSN: 14698749     Source Type: Journal    
DOI: 10.1111/j.1469-8749.2010.03869.x     Document Type: Review

References (50)

1. Scriver CR, Kaufman C, Eisensmith RC, Woo SLC. The hyperphenylalaninemias. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic and Molecular Basis of Inherited Disease. New York: McGraw Hill, 2001: 1667-724.
2. Welsh MC, Pennington BF, Ozonoff S. Neuropsychology of early-treated phenylketonuria: specific executive function deficits. Child Dev 1990; 61: 1967-73.
3. Smith I, Bealey MG, Ades AE. Intelligence and quality of dietary treatment in phenylketonuria. Arch Dis Child 1990; 65: 472-8.
4. de Sonneville LMJ, Schmidt E, Michel U, Batzler U. Preliminary neuropsychological test results. Eur J Pediatr 1990; 149 (Suppl. 1): S39-44.
5. Waisbren SE, Brown MJ, de Sonneville LMJ, Levy HL. Review of neuropsychological functioning in treated phenylketonuria: an information processing approach. Acta Paediatr 1994; 83 (Suppl. 407): 98-103.
6. Weglage J, Pietsch M, Fünders B, Koch HG, Ullrich K. Deficits in selective and sustained attention processes in early treated children with phenylketonuria - result of impaired frontal lobe functions? Eur J Pediatr 1996; 155: 200-4.
7. Diamond A, Prevor MB, Callender G, Druin D. Prefrontal cortex cognitive deficits in children treated early and continuously for PKU. Monogr Soc Res Child Dev 1997; 62: 1-208.
8. Stemerdink N, van der Molen MW, Kalverboer AF, et al. Prefrontal dysfunction in early and continuously treated phenylketonuria. Dev Neuropsychol 1999; 16: 29-57.
9. Burgard P. Development of intelligence in early treated phenylketonuria. Eur J Pediatr 2000; 159 (Suppl. 2): S74-9.
10. Smith ML, Klim P, Hanley WB. Executive function in school-aged children with phenylketonuria. J Dev Phys Disabil 2000; 12: 317-32.
11. White DA, Nortz MJ, Mandernach T, Huntington K. Deficits in memory strategy use related to prefrontal dysfunction during early development: evidence from children with phenylketonuria. Neuropsychology 2001; 15: 221-9.
12. Huijbregts SCJ, de Sonneville LMJ, van Spronsen FJ, Licht R, Sergeant JA. The neuropsychological profile of early and continuously treated phenylketonuria: orienting, vigilance, and maintenance versus manipulation-functions of working memory. Neurosci Biobehav Rev 2002; 26: 697-712.
13. Antshel KM, Waisbren SE. Timing is everything: executive functions in children exposed to elevated levels of phenylalanine. Neuropsychology 2003; 17: 458-68.
14. Gassió R, Artuch R, Vilaseca MA, et al. Cognitive functions in classic phenylketonuria and mild hyperphenylalaninemia: experience in a paediatric population. Dev Med Child Neurol 2005; 47: 443-8.
15. Anderson PJ, Wood SJ, Francis DE, Coleman L, Anderson V, Boneh A. Are neuropsychological impairments in children with early-treated phenylketonuria (PKU) related to white matter abnormalities or elevated phenylalanine levels? Dev Neuropsychol 2007; 32: 645-68.
16. De Roche K, Welsh M. Twenty-five years of research on neurocognitive outcomes in early-treated phenylketonuria: intelligence and executive functions. Dev Neuropsychol 2008; 33: 474-504.
17. Christ SE, Steiner RD, Grange DK, Abrams RA, White DA. Executive function in early-treated phenylketonuria: profile and underlying mechanisms. Mol Genet Metab 2010; 99: S22-32.
18. Dyer CA. Pathophysiology of phenylketonuria. MRDD Res Rev 1999; 5: 104-12.
19. Schmidt E, Burgard P, Rupp A. Effects of concurrent phenylalanine levels on sustained attention and calculation speed in patients treated early for phenylketonuria. Eur J Pediatr 1996; 155 (Suppl. 1): S82-6.
20. Arnold GL, Kramer BM, Kirby RS, et al. Factors affecting cognitive, motor, behavioural and executive functioning in children with phenylketonuria. Acta Paediatr 1998; 87: 565-70.
21. Huijbregts SCJ, De Sonneville LMJ, Licht R, van Spronsen FJ, Sergeant JA. Short-term dietary interventions in children and adolescents with treated phenylketonuria: effects on neuropsychological outcome of a well-controlled population. J Inherit Metab Dis 2002; 25: 419-30.
22. Waisbren SE. Comments on cognition and intelligence in phenylketonuria. Eur J Pediatr 2000; 159 (Suppl. 2): S80-1.
23. Smith I, Beasley MG, Ades AE. Effect on intelligence of relaxing the low phenylalanine diet in phenylketonuria. Arch Dis Child 1991; 66: 311-6.
24. Williams RA, Mamotte CDS, Burnett JR. Phenylketonuria: an inborn error of phenylalanine metabolism. Clin Biochem Rev 2008; 29: 31-41.
25. Mallolas J, Vilaseca MA, Campistol J, et al. Clinical, biomedical, neurological and molecular study of 11 patients with new mutations in PAH gene. Rev Neurol 2000; 31: 907-10.
26. Gramer G, Burgard P, Garbade SF, Lindner M. Effects and clinical significance of tetrahydrobiopterin supplementation in phenylalanine hydroxylase-deficient hyperphenylalaninaemia. J Inherit Metab Dis 2007; 30: 556-62.
27. Waisbren SE, Noel K, Fahrbach K, et al. Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic literature review and meta-analysis. Mol Genet Metab 2007; 92: 63-70.
28. Guttler F, Gulberg P. The influence of mutations on enzyme activity and phenylalanine tolerance in phenylalanine hydroxylase deficiency. Eur J Pediatr 1996; 155 (Suppl. 1): S6-10.
29. Campistol J. [Hyperphenylalaninemia]. In: Sanjurjo P, Baldellou A, editors. [Diagnostic and Processing of Hereditary Metabolic Illnesses]. Madrid: Ergon, 2010: 423-39. [In Spanish].
30. Costello PM, Beasley MG, Tillotson SL, Smith I. Intelligence in mild atypical phenylketonuria. Eur J Pediatr 1994; 153: 260-3.
31. Weglage J, Pietsch M, Feldman R, et al. Normal clinical outcome in untreated females with mild hyperphenylalaninemia. Pediatr Res 2001; 49: 532-6.
32. Weglage J, Schmidt E, Fünders B, Pietsch M, Ullrich K. Sustained attention in untreated non-PKU hyperphenylalaninemia. J Clin Exp Neuropsychol 1996; 18: 343-8.
33. Weglage J, Ullrich K, Pietsch M, Fünders B, Güttler F, Harms E. Intellectual, neurologic, and neuropsychologic outcome in untreated females with nonphenylketonuria hyperphenylalaninemia. Pediatr Res 1997; 42: 378-84.
34. Smith ML, Saltzman J, Klim P, Hanley WB, Feigenbaum A, Clarke J. Neuropsychological function in mild hyperphenylalaninemia. Am J Ment Retard 2000; 105: 69-80.
35. Levy HL, Waisbren SE. Effects of untreated maternal phenylketonuria and hyperphenylalaninemia on the fetus. N Engl J Med 1983; 309: 1269-74.
36. Waisbren SE, Schnell R, Levy HL. Intelligence and personality characteristics in adults with untreated atypical phenylketonuria and mild hyperphenylalaninemia. J Pediatr 1984; 105: 955-8.
37. Levy HL, Waisbren SE, Güttler F, et al. Pregnancy experiences in the woman with mild hyperphenylalaninemia. Pediatrics 2003; 112: 1548-52.
38. Netley C, Hanley WB, Rudner HL. Phenylketonuria and its variants: observations on intellectual functioning. Can Med Assoc J 1984; 131: 751-5.
39. Koch R, Güttler F, Blau N. Mental illness in mild PKU responds to biopterin. Mol Genet Metab 2002; 75: 284-6.
40. Wappner R, Cho S, Kronmal RA, Schuett V, Seashore MR. Management of phenylketonuria for optimal outcome: a review of guidelines for phenylketonuria management and a report of surveys of parents, patients, and clinic directors. Pediatrics 1999; 104: e67.
41. Griffiths P. Neuropsychological approaches to treatment policy issues in phenylketonuria. Eur J Pediatr 2000; 159 (Suppl. 2): S82-6.
42. National Institutes of Health Consensus Development Panel. National Institutes of Health Consensus Development Conference Statement: phenylketonuria: screening and management, 16-18 October 2000. Pediatrics 2001; 108: 972-82.
43. The National Society for Phenylketonuria (United Kingdom). Management of PKU. 2nd edn. London: The National Society for Phenylketonuria, 2004.
44. Hendriksz CJ, Walter JH. Update on phenylketonuria. Curr Paediatr 2004; 14: 400-6.
45. Ogier de Baulny H, Abadie V, Feillet F, de Parscau L. Management of phenylketonuria and hyperphenylalaninemia. J Nutr 2007; 137: S1561-3.
46. Burgard P, Rey F, Rupp A, Abadie V, Rey J. Neuropsychologic functions of early treated patients with phenylketonuria, on and off diet: results of a cross-national and cross-sectional study. Pediatr Res 1997; 41: 368-74.
47. Huijbregts S, de Sonneville L, Licht R, Sergeant J, van Spronsen F. Inhibition of prepotent responding and attentional flexibility in treated phenylketonuria. Dev Neuropsychol 2002; 22: 481-99.
48. Huijbregts SCJ, de Sonneville LMJ, Licht R, van Spronsen FJ, Verkerk PH, Sergeant JA. Sustained attention and inhibition of cognitive interference in treated phenylketonuria: associations with concurrent and lifetime phenylalanine concentrations. Neuropsychologia 2002; 40: 7-15.
49. Committee on Genetics. Maternal phenylketonuria. Pediatrics 2008; 122: 445-9.
50. Koch R, Trefz F, Waisbren S. Psychosocial issues and outcomes in maternal PKU. Mol Genet Metab 2010; 99: S68-74.